Status:

RECRUITING

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma

Lead Sponsor:

Grit Biotechnology

Conditions:

Advanced Lung Adenocarcinoma;Adult

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study is a Multiple centers, open design aimed at evaluating the safety,efficacy and Production feasibility of Autologous Tumor-Infiltrating Lymphocyte (GTE-001 injection ) for treatment of patie...

Eligibility Criteria

Inclusion

  • 1\. Voluntarily join the study, signed informed consent form, willing and able to comply with the study protocol;
  • 2\. Age ≥18 years old;
  • 3\. Advanced lung adenocarcinoma that progresses after recurrence or first-line chemotherapy;
  • 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  • 5\. Expected survival time of ≥ 3 months;
  • 6\. Good function of vital organs;
  • 7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.

Exclusion

  • Subject has previously received an allogeneic stem cell transplant or organ allograft,Subject has previously received engineered cell therapy,Prior FOLR1 directed therapy is not allowed unless it had been with an approved agent in the indication;
  • Subject has undergone surgery or received radiotherapy, immunotherapy, targeted therapy agents, anticancer vaccines, systemic steroids, or chemotherapy within 2 weeks of enrolment. Targeted agents, such as tyrosine kinase inhibitors, may be continued until 5 half-lives before enrolment;
  • Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 12 months after cell infusion;
  • History of central nervous system (CNS) disorder,History of autoimmune disease,History of primary immunodeficiency;

Key Trial Info

Start Date :

July 18 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 18 2027

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT06491225

Start Date

July 18 2024

End Date

July 18 2027

Last Update

February 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing GoBroad Hospital

Beijing, Beijing Municipality, China, 102200

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma | DecenTrialz